Clinical Trials Logo

Clinical Trial Summary

40 CRPS patients will be recruited over a three-year period (target of 160 patients at all sites). Assessment of exclusion criteria will be undertaken during initial recruitment. Exclusion criteria are: <18 years; a second chronic pain syndrome that would interfere with pain rating; psychiatric comorbidity; pain in both hands or feet; pregnancy or breastfeeding; sympathectomy in the affected limb; use of topical medication; known sensitivity to alpha 1- adrenoceptor agonists or other contraindications. Patients will maintain their regular oral medications throughout the study period. Assessment of sympathetically maintained pain (SMP) will require an intradermal dose of Phenylephrine to rekindle SMP and mechanical hyperalgesia. Clonidine will be used to control for affects of algometer fiction and may inhibit SMP by inhibiting the release of more norepinephrine from sympathetic nerve terminals. Skin biopsies will be obtained under sterile conditions from a site of mechanical or thermal hyperalgesia using a 3mm diameter skin biopsy punch under local anesthesia. Samples from a mirror image site on the contralateral body side will also be taken.


Clinical Trial Description

Patients diagnosed with CRPS and control subjects will be enrolled in the study. The CRPS participants will be administered with phenylephrine (day 1) and clonidine (day 2). The control participants will not receive any intervention. The aim of this study is to determine if expression of α1-adrenoceptors (α1-AR) altered in the skin of a subgroup of patients whose pain is associated with increased adrenergic sensitivity after nerve trauma. Increased adrenergic sensitivity will be determined by assessing pain in patients after administration of phenylephrine on day 1. Expression of α1-AR will be determined by taking skin biopsies on day 2 after administration of clonidine. Then, we will compare the expression of α1-AR in patients who were classified as having increased adrenergic sensitivity versus those who were not. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01813149
Study type Interventional
Source The Cleveland Clinic
Contact
Status Terminated
Phase N/A
Start date August 2012
Completion date December 2016

See also
  Status Clinical Trial Phase
Completed NCT01512121 - Spinal Cord Stimulation and Functional MRI
Completed NCT02265848 - High Frequency Stimulation Trials in Patients With Precision Spinal Cord Stimulator System Phase 4
Active, not recruiting NCT01508676 - Effects of Pennsaid on Clinical Neuropathic Pain N/A
Terminated NCT03560986 - Efficacy and Safety of Intravenous Neridronic Acid in Complex Regional Pain Syndrome (CRPS) Phase 3
Terminated NCT03530345 - Efficacy and Safety of Intravenous Neridronic Acid in CRPS Phase 3
Completed NCT03285113 - A Study to Confirm the Safety of High Frequency DRG Stimulator in Patients With Chronic Lower Limb Pain N/A
Recruiting NCT03686748 - Two Point Discrimination Early Phase 1
Completed NCT01926119 - TMS for CRPS - Pilot Study N/A
Completed NCT02067273 - Transcranial Magnetic Stimulation (TMS) for CRPS N/A
Completed NCT01118988 - Peer Mentorship: An Intervention To Promote Effective Pain Self-Management In Adolescents N/A
Active, not recruiting NCT02800863 - TARGET Post-Approval Study